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EDITORIAL Open Access
Inflammasome lights up in systemic
sclerosis
John Henderson and Steven O’Reilly*
See related research by Artlett et al., https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1331-z.
Abstract
Systemic sclerosis (SSc) is a pro-fibrotic condition with a
poorly understood aetiology. Evidence presented by
Artlett et al. in this issue suggests that the microRNA
miR-155 is key, with its involvement dependent on the
NLRP3 inflammasome. This links epigenetic events with
inflammasome signalling in SSc and opens the door to
new therapeutic strategies for the treatment of SSc.
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Main text
Systemic sclerosis (SSc) is an idiopathic autoimmune dis-
ease characterised by inflammation, vascular problems,
cytokine dysregulation and ultimately fibrosis, which ac-
counts for the poor prognosis and eventual mortality. At
present, treatment of SSc is limited by incomplete under-
standing of pathogenesis and although immunosupressive
strategies are beneficial for lung and skin, the benefits are
often modest. Excessive collagen production by over-
activated fibroblasts is the key driver of the fibrosis, with a
spike in the innate immune response and, in particular,
Toll-like receptor (TLR) signalling recently identified as
responsible for the fibroblast activation.
Since its discovery, the NLR family pyrin domain con-
taining 3 (NLRP3) inflammasome has become increasingly
implicated in numerous inflammatory conditions, raising
the suspicion that it has a key role in SSc. This suspicion
has been confirmed by Artlett et al. [1], who present a
compelling case for the NLRP3 inflammasomme-
mediated importance of miR-155 (microRNA-155) in SSc,
an outcome that carries high clinical significance. They
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show that NLRP3-deficient fibroblasts and fibroblasts
treated with the caspase-1 inhibitor YVAD potently re-
duced miR-155 expression and decreased collagen synthe-
sis, with the addition of SSc-promoting stimuli having no
effect—thus, it appears the inflammasome regulates miR-
155 and collagen levels. It is suggested that the interplay
between the innate immune system and microRNA ex-
pression and the subsequent activation of fibroblasts have
a dominant pathogeneic role in SSc.
In recent years small non-coding microRNAs have
emerged as key players in a number of diseases [2], with
SSc apparently now added to their number. Widely
regarded as the ‘fine tuners’ of gene expression, a single
microRNA can have hundreds of targets. Artlett et al. [1]
show that miR-155 is elevated in SSc dermal and lung fi-
broblasts and that deletion of miR-155 in mouse cells
treated with bleomycin (a model for scleroderma) reverts
collagen synthesis back to basal levels. They then per-
formed an elegant experiment whereby re-introducing
miR-155 back into the knockout cells via a retroviral vec-
tor caused an upregulation of collagen which was aug-
mented in the presence of bleomycin—outlining the
importance of miR-155 in SSc. This is underscored by the
fact that, despite the transfection efficacy of the cells to
take up the vector being only 10% on average, a dramatic
increase in collagen was still seen.
From a therapeutic perspective this central importance of
miR-155 is very exciting given a miR-155 inhibitor has re-
cently been shown to effectively treat dermal fibrosis in a
mouse model [3], with these results suggesting that, if ap-
plied intravenously, it could have a similar effect against
SSc fibrosis.
Mechanistically, however, the big question of how en-
hanced miR-155 drives collagen synthesis remains un-
answered. We too have seen elevated miR-155 levels in SSc
patients in association with increased collagen, but the tar-
gets of miR-155 that mediate this increase are still under re-
view, with inhibitors of collagen regulation appearing likely
candidates. Artlett et al. [1] show a dependence of mir-155
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on downstream IL-1 signalling, with the IL-1 receptor an-
tagonist (IL-1RA) shown to block increased collagen syn-
thesis in the presence of bleomycin or the miR-155 vector.
These findings are substantiated by Abtahi et al. [4], who
found that single nucleotide polymorphisms (SNPs) in the
IL-1 gene cluster may affect SSc susceptibility. This sug-
gests that using IL-1 receptor antagonists may be useful in
SSc. Indeed a clinical trial is currently underway to deter-
mine the efficacy of using an IL-1 receptor blocker in SSc,
with results eagerly anticipated given such drugs are highly
efficient in IL-1-driven diseases such as hereditary systemic
inflammatory disorders and gout.
Artlett et al. [1] expand on this by going on to propose a
feed-forward mechanism whereby IL-1 upregulates miR-
155, which itself interacts with the inflammasome to pro-
mote IL-1 activation, providing a feasible explanation for
how chronic collagen over-expression could occur. The
authors don’t identify any specific targets of miR-155 prior
to inflammasone upregulation within this mechanism and
the molecules being repressed remain to be elucidated.
miR-155 is induced by TLR stimulation and is used to
negatively regulate TLR signalling. The authors demon-
strate that IL-1β induces miR-155 expression, which may
be a mechanism of negative feedback. Taken together,
these results raise the possibility of the inflammasome
functioning as a nexus for the currently unknown triggers
leading to SSc pathogenesis. This fits with the NLRP3
inflammasone’s sensitivity to environmental stimuli such
as toxins and drugs, which it has been speculated may be
the triggers for SSc. Consequently, enhanced NLRP3 ac-
tivity and IL-1β production in response to an unknown
external insult may be what fuels the disease progression.
Finally, Artlett et al [1] show the dependence of the no-
torious master regulator of fibrosis, transforming growth
factor-β1 (TGF-β1), on miR-155, with bleomycin unable
to induce TGF-β1 in miR-155 knockout fibroblasts. This
further emphasises that miR-155 is a key proponent of the
fibrosis observed in SSc and may also play a key role in
other pro-fibrotic diseases where TGF-β1 is involved.
Quite how miR-155 regulates TGF-β1 remains unknown
and is likely to be an indirect mechanism as no seed re-
gion in the 3′ UTR is predicted to bind miR-155.
One way in which this work could be taken forward
would be to replicate the experiments performed in this
study in vivo, using the same mouse models. Additionally,
the transgenic miR-155 overexpressing mouse model
Rm155LG could be utilised to verify that enhanced miR-
155 expression increases collagen production and fibrosis
susceptibility in vivo.
Most importantly of all, the dependence of miR-155-
driven effects specifically on NLRP3 inflammasome activity
also opens up new therapeutic avenues, with the recently
developed small molecule inhibitor of the NLRP3 complex
MCC950 touted as an excellent candidate for treating
NLRP3-related pathologies [5], a theory that could be
probed by testing MCC950 on the previously mentioned
models of SSc. MCC950 inhibits NLRP3 in response to ca-
nonical and non-canonical ligands, which is important as
the ligands for activation of NLRP3 in SSc are not yet
known. In liver fibrosis it has been demonstrated that
NLRP3 activation occurs in response to palmitic acid and
the transformation of the quiescent hepatic cell to a hepatic
stellate cell [6]; hence, we postulate that similar ligands
could be activating the inflammasome in SSc.
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